Geron (FRA:GON) Other Financing: €0.0 Mil (TTM As of Mar. 2026)


FRA:GON Geron Corp FRA:GON
37 GF Score
Price €1.36
GF Value €6.15
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Other Financing?

Geron FRA:GON +1.00% 37 Other Financing is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:GON with a GF Score™ of 37/100 and a GF Value™ of €6.15 (Possible Value Trap). The stock has 4 warning signs investors should review.

Geron's Other Financing for the three months ended in Mar. 2026 was €0.0 Mil.

Geron's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

Geron Other Financing Historical Data

* Premium members only.

The historical data trend for Geron's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Other Financing Chart

Geron Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.90 16.38 109.11 151.92 0.00

Geron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:GON
37GF Score
Geron Corp FRA:GON
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geron Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €0.0 Mil mean?
Geron (FRA:GON) has a Other Financing of €0.0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Geron and its competitors.
Is Geron's Other Financing too high?
Geron's current Other Financing is €0.0 Mil. Overall, Geron has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Other Financing compare to SPRY and PHAT?
Geron's Other Financing of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Geron and its competitors. Geron's current Other Financing is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €6.15, compared to a current price of €1.36 — trading 77.9% below its estimated fair value. The current Other Financing is €0.0 Mil. Geron's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Geron (FRA:GON), the current Other Financing is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Geron (FRA:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.36 is trading 77.9% below its estimated GF Value™ of €6.15. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for FRA:GON:

  • Other Financing: €0.0 Mil
  • GF Value™: €6.15 vs. price of €1.36 (77.9% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
37GF Score

Get the complete analysis for FRA:GON

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price
€6.15
GF Value